Abstract 296: Pre-treatment clinical laboratory tests indicative of metabolic status are associated with survival in patients with non-small cell lung cancer

The value of serum pre-treatment laboratory tests for prognostic purposes in non-small cell lung cancer (NSCLC) is mixed, with inconsistent results. This study was designed to identify pre-treatment routine laboratory tests indicative of a patient9s overall metabolic status, as predictors of NSCLC survival. We assessed seven pre-treatment serum laboratory test levels, including alanine aminotransferase, albumin, alkaline phosphatase, glucose, lactate dehydrogenase, total bilirubin, and total protein in 2,675 NSCLC patients, among which 2,201 patients were Caucasians. There were 623 early stage and 2,052 advanced stage NSCLC patients. To minimize the effect of treatment heterogeneity, we focused on subgroups of patients with similar treatment regimens. We studied 978 advanced stage NSCLC patients who were treated with platinum-based chemotherapy. Compared to those with pre-treatment laboratory test levels within the normal range, lower than normal levels of albumin [adjusted hazard ratio (HR) = 1.47, 95% confidence interval (CI): 1.15-1.87, P Citation Format: Fanmao Zhang, Qing H. Meng, Yuanqing Ye, Michelle AT Hildebrandt, Maosheng Huang, Xifeng Wu. Pre-treatment clinical laboratory tests indicative of metabolic status are associated with survival in patients with non-small cell lung cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 296. doi:10.1158/1538-7445.AM2014-296